Akso Health

We do not see evidence of owner‑operator alignment or a proven record of superior capital deployment. The CEO holds no reported ordinary shares, while control resides with Webao Limited via 7.98 million super‑voting Class B shares (20 votes per share).

Prior ICFR weaknesses were noted in FY2025 and the FY2026 audit still includes going‑concern language. Strategy shifts and large write‑downs suggest weak execution.